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Clozapine, fluoxetine, and benztropineassociated ileus: Case report
Pegah Pajouhi, M.D. (PGY1), James A. Bourgeois, O.D., M.D.

ABSTRACT
Gastrointestinal complications of anticholinergic medications are
prevalent, potentially life-threatening, and could be more actively
prevented. We present a case report of an ileus that required surgical
intervention and developed in the context of clozapine, benztropine, and
fluoxetine use. The case exemplifies the potential anticholinergic
toxicities of clozapine and benztropine as well as possible
pharmacokinetic interactions between fluoxetine, clozapine, and
benztropine. We discuss ways to minimize the likelihood of
anticholinergic complications with these medications.

CASE REPORT
A 50-year-old schizophrenic man presented with diffuse abdominal pain
radiating to his flanks, cramping, green emesis, and no bowel movements for
three days. Outpatient medications included clozapine 200 mg q AM and
400 mg qhs, benztropine 2 mg bid, and fluoxetine 20 mg q AM. He had a
history of smoking one and one-half packs of cigarettes daily for 35 years.
His abdomen was tender in the right lower quadrant and was distended and
tympanic; bowel sounds were hypoactive. Dilated large bowel loops were
visible in abdominal plain film and dilated proximal bowel was noted on CT
scan. His treatment team was unable to resolve the small bowel obstruction
through bowel rest and decompression. Therefore, exploratory laparotomy
was performed. Surgery revealed a massively dilated jejunum with a clear
transition point to decompressed distal bowel; no mechanical source of
obstruction was identified.
He remained off his medications until post-op day 2, at which time he was
re-started on fluoxetine 20 mg q AM and benztropine 2 mg bid. Clozapine
200 mg q AM and 400 mg qhs was re-started on post-op day 6. On post-op
day 12, the Psychiatric Psychosomatic Medicine (PSM) Service evaluated
the patient. The PSM Service noted the possibilities of a pharmacokinetic
clozapine-fluoxetine drug interaction (inhibition of clozapine metabolism by
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concurrent fluoxetine) and/or a pharmacodynamic clozapine-benztropine
drug interaction (both agents have significant anticholinergic effects)
causing or exacerbating the ileus through an anticholinergic mechanism.
Recommendations to discontinue clozapine and benztropine then to start
quetiapine 200 mg q AM and 400 mg qhs were implemented. Serum
clozapine levels were not available. On post-op day 15, the patient reported
relief of abdominal pain and had reduced abdominal distension. He was
transferred to a psychiatric facility.

DISCUSSION
Clozapine is an atypical antipsychotic that is an antagonist at numerous
receptors: it is anti-serotonergic (5-HT2, 5-HT3), anti-alpha 1 adrenergic,
antihistaminic (H1), and antimuscarinic. Its potent preferential blockade of
dopamine D1 and D4 receptors are likely significant contributors to its
antipsychotic effects (1). Clozapine produces a dose-dependent increase in
anticholinergic activity and is primarily hepatically metabolized by P450
1A2 with additional secondary pathways (2). If used concurrently with
clozapine, fluoxetine and fluvoxamine increase the risk of developing
anticholinergic effects; these medications increase clozapine levels by 50%
and three- to four-fold, respectively, due to inhibition of P450 1A2, 2C9/19,
2D6, and 3A4. Caffeine consumption may increase clozapine levels (by
inhibiting P450 1A2), while smoking may decease clozapine levels (by
induction of P450 1A2) (3).
Gastrointestinal effects associated with clozapine include constipation,
gastric outlet obstruction, prolonged postoperative ileus, and peritonitis with
bowel perforation; fatalities have been reported (1, 4-10). The prevalence of
developing intestinal side effects, ranging from constipation to bowel
perforation, while taking clozapine has been reported as high as 33% (5-7).
The significant anticholinergic effects of benztropine, commonly
prescribed for EPS, may be especially important when added to the
anticholinergic effects of clozapine. There have been reported cases of
intestinal dysmotility attributed to benztropine alone as the primary
anticholinergic agent (11-13). Minzenberg et al. have produced a useful
table of the relative anticholinergic potencies of various psychotropic agents
(14). Their table includes both a “pharmacological index” (based on
published in vitro studies of muscarinic antagonism) and a “clinical index”
(based on clinician ratings of anticholinergic side effects). For both indices,
benztropine is given a value of 1. Clozapine is among the most
anticholinergic of the atypical antipsychotics; it has a “pharmacological
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index” of 8 mg clozapine as the anticholinergic equivalent of 1 mg
benztropine and a “clinical index” of 85 mg clozapine as the anticholinergic
equivalent of 1 mg benztropine (14). Using the table of Minzenberg et al.,
we find that our patient initially had a combined anticholinergic effect
totaling 79 benztropine equivalents by the “pharmacological index” and 11
by the “clinical index”; after clozapine and benztropine were discontinued
and quetiapine was started, the patient received only 0.8 benztropine
equivalents by the “pharmacological index” and 2.6 by the “clinical index”
(14).
Long-term, treatment-refractory psychiatric inpatients have additional risk
factors for developing an ileus. One factor is the compounding effect of a
long history of high-dose antipsychotic medication that leads to reduced
bowel motility. A second factor is the reduction of daily physical activity
levels among patients living in long-term inpatient psychiatric facilities. At
the Atascadero State Hospital in California, for instance, where 60% of
patients on clozapine were found to have constipation, the staff implemented
the Clozapine Constipation Protocol in 1995 (8). The protocol involves
abdominal imaging and physical assessment prior to starting the medication,
slow dosage increases (maximum of 100mg/day each week), daily
documentation of bowel and dietary habits, and input from a dietitian who
encourages a high-fiber diet, adequate fluid intake, and regular physical
exercise. Most of the patients on clozapine receive a stool softener or a bulkforming laxative, and some are prescribed bethanechol. Taking these
measures resulted in a significant decline in both the prevalence of
constipation and the number of patients transferred to the medical unit for
the treatment of clozapine-induced gastrointestinal dysmotility (8).
We offer the following five suggestions to avoid adverse bowel events in
patients on clozapine and/or benztropine: 1) increased surveillance for bowel
dysfunction in patient receiving the medications 2) proactive management of
early bowel dysmotility to prevent serious outcomes 3) avoidance of both
pharmacodynamic and pharmacokinetic drug-drug interactions that increase
anticholinergic effects of clozapine (specific avoidance of fluoxetine,
fluvoxamine, or benztropine with clozapine) 4) use of alternative atypical
antipsychotic medications with lower degrees of anticholinergic activity in
patients at higher risk of bowel dysmotility and 5) avoidance of benztropine
in patients who have had clinical sings of decreased intestinal motility.
When clozapine is necessary despite a history of clozapine-induced ileus
(e.g. in patients who are resistant to other medications), clinicians may try
the following after the patient has fully recovered gastrointestinal motility:
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1) restart clozapine at a lower dose while continuing to avoid fluoxetine,
fluvoxamine, and benztropine; or 2) cautiously increase the clozapine dose
while continuing to avoid these other agents. When possible, monitoring of
serum clozapine levels may help.
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